Onyx Seeks Suitors After Rejecting Amgen’s Bid
July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Most Recent Videos
"Preserving Bombardier C-Series Key Amid 7,500 Job Cuts"
09:19 - Bombardier has announced it will slash 7,500 jobs during a second round of job cuts within the past 8 months. Bloomberg Intelligence Analyst George Ferguson explains whether these cost saving measures were necessary as the struggling aircraft maker awaits $1 billion in federal aid from the Canadian government on Bloomberg TV Canada's The Daily Brief. (Source: Bloomberg)